Active Follow-up in Patients with Localized Prostate Cancer: Evaluation of Long-term Results

S.O. Vozianov, V.M. Grygorenko, R.O. Danylets, A.V. Bardin, L.V. Pereta

Abstract


Among the clinical recommendations one of the standard approaches in the treatment of prostate cancer is active follow-up. For 13 years, under the supervision there were 85.7 % of patients. Overall 3-, 5- and 7-year survival rate was 93.2 ± 4.6 %, 70.8 ± 9.1 % and 50.9 ± 10.2 %, respectively. 14.3% of patients died due to comorbidities. The average time of survival was 136 months.
These data substantiate the feasibility of active follow-up from medical, social and economic point of view. Optimal results can be achieved with the right selection, the criteria of which are: the level of prostate-specific antigen ≤ 10 ng/ml, Gleason grading score ≤ 6, age, multiple organ pathology.


Keywords


prostate cancer; active follow-up; Gleason grading; prostate specific antigen

References


Berger I.M. Prostate cancer in senior adults: over- or undertreated? / Berger I., Böhmer F., Ponholzer A., Böhmer F. [et al.] // S. Med. Wochenschr. — 2009. — Vol. 159, № 21–22. — P. 521-528.

Gittes R.F. Carcinoma of the prostate / R.F. Gittes // Engl. J. Med. — 1991. — Vol. 324(4). — P. 236-245.

Koppie T.M. Patterns of treatment of patientswithprostate cancer initially managed with surveillance: results from The CaPSUREdatabase. Cancer of the Prostate trategic Urological Research Endeavor / T.M. Koppie, G.D. Grossfeld, D. Miller [et al.] // J. Urol. — 2000. — Vol. 164(l). — P. 81-88.

Johansson J.E. Natural History of Early, Localized Prostate Cancer / J.E. Johansson, O. Andren, S.O. Andersson et al. // JAMA. — 2004. — 291. — 2713-2719.

Klotz L. Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer / L. Klotz, L. Zhang, A. Lam, R. Nam, A. Mamedov, A. Loblaw // J. Clin. Oncol. — 2010. — Vol. 1, № 28(1). — P. 126-131.




DOI: https://doi.org/10.22141/2307-1257.0.2.04.2013.85343

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 KIDNEYS

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru